吳麗敏,陳立祥,梁麗娟,王 箏,王 淼,劉少偉,熊云昭,王 萱,許慶友
( 1.河北醫(yī)科大學(xué)研究生學(xué)院,河北石家莊 050091;2.河北中醫(yī)學(xué)院中西醫(yī)結(jié)合學(xué)院內(nèi)科教研室,河北省中西醫(yī)結(jié)合肝腎病重點(diǎn)實(shí)驗(yàn)室,河北石家莊 050091)
?
依普利酮下調(diào)SGK-1表達(dá)抑制梗阻性腎病細(xì)胞增殖的研究
吳麗敏1,2,陳立祥1,梁麗娟1,王箏2,王淼1,劉少偉2,熊云昭1,王萱1,許慶友1,2
( 1.河北醫(yī)科大學(xué)研究生學(xué)院,河北石家莊050091;2.河北中醫(yī)學(xué)院中西醫(yī)結(jié)合學(xué)院內(nèi)科教研室,河北省中西醫(yī)結(jié)合肝腎病重點(diǎn)實(shí)驗(yàn)室,河北石家莊050091)
關(guān)鍵詞:依普利酮;腎間質(zhì)纖維化;細(xì)胞增殖; UUO; PCNA; SGK-1; TGF-β1
許慶友( 1958-),男,博士,教授,主任醫(yī)師,博士生導(dǎo)師,研究方向:腎臟病中西醫(yī)結(jié)合臨床及基礎(chǔ),通訊作者,Tel: 0311-89926298,E-mail: qingyouxu@ sohu.com
腎間質(zhì)纖維化( RIF)是各種慢性腎臟疾病發(fā)展到終末期腎衰竭的共同病理改變[1]。其主要病理特點(diǎn)為臟器萎縮、細(xì)胞外基質(zhì)( ECM)過度積聚和細(xì)胞增生。研究表明,血清糖皮質(zhì)激素誘導(dǎo)蛋白激酶1( SGK-1)、轉(zhuǎn)化生長因子β1( TGF-β1)等致纖維化因子在醛固酮的誘導(dǎo)下促進(jìn)細(xì)胞增殖及ECM積聚,造成腎臟硬化[2-3]。
本實(shí)驗(yàn)采用單側(cè)輸尿管結(jié)扎梗阻大鼠模型,激活腎素-血管緊張素-醛固酮( RAAS)系統(tǒng),誘導(dǎo)醛固酮活化致腎間質(zhì)纖維化。觀察其阻斷劑依普利酮對(duì)細(xì)胞增殖標(biāo)志物增殖細(xì)胞核抗原( PCNA)、血清糖皮質(zhì)激素誘導(dǎo)蛋白激酶1( SGK-1)、轉(zhuǎn)化生長因子β1( TGF-β1)的調(diào)控作用,探討依普利酮拮抗醛固酮活化所致腎間質(zhì)纖維化的可能作用機(jī)制。
1.1實(shí)驗(yàn)動(dòng)物及分組選用清潔級(jí)♀Wistar大鼠36只,體質(zhì)量( 200±20) g,購自河北醫(yī)科大學(xué)動(dòng)物實(shí)驗(yàn)中心,隨機(jī)分為假手術(shù)組、UUO組及依普利酮組( n =12)。
1.2藥物、試劑和主要儀器依普利酮為美國Pfizer公司產(chǎn)品,日本Research Diets.Inc公司根據(jù)動(dòng)物進(jìn)食量及藥物用量( 100 mg·kg-1·d-1)按1. 25 g·kg-1加入飼料中; PCNA抗體選用Epitomics產(chǎn)品; SGK-1抗體選用Affbiotech產(chǎn)品; TGF-β1、GAPDH抗體均選用Bioworld Technology產(chǎn)品;電泳儀及電泳槽(北京六一公司),OLYMPUS VANOX PM-10AD型顯微照相儀(日本OLYMPUS公司),LEICA RM 2245型石蠟切片機(jī)(德國LEICA上海分公司)。
1.3造模方法及給藥實(shí)驗(yàn)動(dòng)物適應(yīng)性喂養(yǎng)1周后,復(fù)制梗阻性腎病模型,10%水合氯醛注射麻醉,于腹部左側(cè)切開,游離左側(cè)輸尿管,于輸尿管上1/3處和中1/3處結(jié)扎后切斷并縫合,假手術(shù)組僅游離輸尿管。治療組給以大鼠依普利酮100 mg·kg-1·d-1。治療10 d后摘取左側(cè)腎臟,4%多聚甲醛中固定、石蠟包埋,切片行常規(guī)HE、Masson及免疫組化染色;剩余組織-70℃保存用于Western blot檢測(cè)蛋白表達(dá)。
1.4觀察指標(biāo)及方法
1.4.1 HE、Masson染色觀察腎臟組織形態(tài)學(xué)改變
1.4.2免疫組化檢測(cè)PCNA、SGK-1、TGF-β1表達(dá)采用SABC法檢測(cè),一抗?jié)舛染鶠?∶100。
1.4.3 Western blot檢測(cè)PCNA、SGK-1、TGF-β1蛋白表達(dá)冰凍腎組織100mg加裂解液(含蛋白酶抑制劑) 0. 4 mL,提取蛋白并測(cè)定含量;取樣品上樣蛋白20μg,電泳后轉(zhuǎn)膜,5%脫脂牛奶封閉,加入一抗SGK-1、PCNA、GAPDH抗體( 1∶1000),TGF-β1抗體( 1∶500),4℃過夜,清洗3次,加入兔二抗( 1∶20 000)孵育后顯影,與所得內(nèi)參進(jìn)行校正后比較。
1.5統(tǒng)計(jì)學(xué)方法數(shù)據(jù)資料結(jié)果采用SPSS17. 0統(tǒng)計(jì)軟件進(jìn)行統(tǒng)計(jì)分析。采用單因素方差分析( Oneway ANOVA),數(shù)值變量以±s表示。
2.1各組大鼠腎臟組織病理學(xué)改變HE染色結(jié)果假手術(shù)組腎臟偶見炎性細(xì)胞浸潤,間質(zhì)無水腫,小管無擴(kuò)張,上皮細(xì)胞排列整齊; UUO組大鼠腎臟有大量炎性細(xì)胞浸潤,腎小管擴(kuò)張明顯,上皮細(xì)胞脫落;依普利酮組遠(yuǎn)端小管擴(kuò)張程度及上皮細(xì)胞脫落與UUO組大致相同,但炎性細(xì)胞浸潤較UUO組明顯減少( Fig 1)。Masson染色結(jié)果:假手術(shù)組大鼠腎臟間質(zhì)中可見少量膠原纖維成分表達(dá),腎小管和腎小球基底膜結(jié)構(gòu)清晰。UUO組腎小管間質(zhì)中有大量膠原纖維成分沉積,腎臟結(jié)構(gòu)紊亂。依普利酮組膠原纖維成分表達(dá)與假手術(shù)組相比增多,與UUO組相比膠原纖維成分明顯減少( Fig 2)。
2.2腎組織PCNA的免疫組化檢測(cè)PCNA在假手術(shù)組中僅有少量表達(dá),見于腎小管。模型組陽性細(xì)胞明顯增多,以腎小管上皮細(xì)胞及間質(zhì)表達(dá)為甚;依普利酮組與模型組相比,PCNA陽性細(xì)胞數(shù)明顯減少,主要見于腎小管( Fig 3)。
2.3腎組織SGK-1及TGF-β1的表達(dá)假手術(shù)組SGK-1及TGF-β1呈弱表達(dá),主要表達(dá)于腎小管上皮細(xì)胞,SGK-1以遠(yuǎn)端小管為主;模型組中SGK-1及TGF-β1表達(dá)明顯增強(qiáng),主要見于腎小管上皮及間質(zhì)細(xì)胞:依普利酮組SGK-1及TGF-β1表達(dá)范圍及強(qiáng)度較模型組均明顯減弱( Fig 4、5)。
Fig 1 HE staining of kidney in rats with UUO(×200)
Fig 2 Masson staining of kidney in rats with UUO(×200)
Fig 3 Expression of PCNA in UUO rats with immunohistochemistry (×200)
Fig 4 Expression of SGK-1 in UUO rats with immunohistochemistry(×100)
Fig 5 Expression of TGF-β1in UUO rats with immunohistochemistry(×200)
2.4腎組織PCNA、SGK-1及TGF-β1的蛋白表達(dá)
采用Western blot檢測(cè)腎組織PCNA、SGK-1及TGF-β1蛋白表達(dá),結(jié)果顯示模型組PCNA、SGK-1及TGF-β1表達(dá)與假手術(shù)組相比明顯增強(qiáng),差異有統(tǒng)計(jì)學(xué)意義( P<0. 01) ;依普利酮組的表達(dá)與模型組相比明顯減弱,差異有統(tǒng)計(jì)學(xué)意義( P<0. 05),見Tab 1、Fig 6。
Tab 1 The protein expression of PCNA,SGK-1,TGF-β1in UUO rats with Western blot (±s,n =3)
Tab 1 The protein expression of PCNA,SGK-1,TGF-β1in UUO rats with Western blot (±s,n =3)
**P<0. 01 vs sham;△P<0. 05 vs UUO
Group PCNA/GAPDH SGK-1/GAPDH TGF-β1/GAPDH Sham 0.4579±0.0458 0.4608±0.1561 0.0826±0.0166 UUO 1.1113±0.1922** 1.5957±0.2680** 0.7216±0.0792**Epl 0.6479±0.2075△ 1.0605±0.2224△ 0.3 680±0.0656△
Fig 6 Expression of PCNA,SGK-1,TGF-β1in UUO rats with Western blot
慢性腎衰竭是所有慢性腎臟疾病發(fā)展的最終結(jié)局,其病理改變是腎間質(zhì)纖維化。腎間質(zhì)纖維化常伴有腎小管萎縮、間質(zhì)炎性細(xì)胞浸潤、成纖維細(xì)胞聚集以及間質(zhì)基質(zhì)沉積等特征性病理改變。隨著對(duì)RAAS系統(tǒng)的深入了解,研究證實(shí)RAAS的激活是引起慢性腎臟病的重要因素之一[4],醛固酮作為RAAS系統(tǒng)的重要效應(yīng)分子,可作為獨(dú)立危險(xiǎn)因素直接參與慢性腎臟疾病的進(jìn)展[5]。新的研究發(fā)現(xiàn),醛固酮除可調(diào)節(jié)腎臟電解質(zhì)及水的排泄外,也參與炎性損傷、氧化應(yīng)激、膠原沉積等多種病理反應(yīng)[6]。細(xì)胞增殖及ECM的沉積是導(dǎo)致腎小球硬化和間質(zhì)纖維化的重要因素之一。細(xì)胞增殖多出現(xiàn)在ECM沉積之前,并持續(xù)存在于ECM的沉積及腎間質(zhì)纖維化發(fā)展過程中[7],故抑制醛固酮活化誘導(dǎo)的腎小管上皮細(xì)胞及間質(zhì)細(xì)胞增殖作用可相對(duì)減少ECM的沉積,減緩腎間質(zhì)纖維化進(jìn)程,對(duì)于減緩慢性腎臟病的進(jìn)展具有重大意義。
PCNA在腎臟病的進(jìn)展中反映著細(xì)胞的增殖狀態(tài),有研究表明UUO術(shù)后3d腎臟PCNA表達(dá)明顯增強(qiáng)[8],我們的研究也發(fā)現(xiàn)梗阻24 h后PCNA陽性細(xì)胞開始增多并持續(xù)于整個(gè)實(shí)驗(yàn)(結(jié)果待發(fā)表),主要以上皮細(xì)胞及間質(zhì)細(xì)胞為主,增殖的細(xì)胞分泌細(xì)胞外基質(zhì)參與纖維化的進(jìn)展。故有效抑制細(xì)胞增殖對(duì)減緩腎間質(zhì)纖維化具有重要作用。
細(xì)胞增殖與多種血管活性物質(zhì)及細(xì)胞生長因子等有關(guān),以往對(duì)Ang II較為重視,近幾年通過對(duì)醛固酮的深入研究,醛固酮活化在腎臟病的損傷中有著更為重要的意義,醛固酮活化的作用途徑有多種,其中SGK-1途徑在炎性損傷中發(fā)揮著重要作用。SGK-1的經(jīng)典作用是對(duì)腎小管中鈉離子代謝的調(diào)節(jié)。此外SGK-1是重要的細(xì)胞內(nèi)信號(hào)轉(zhuǎn)導(dǎo)通路及細(xì)胞磷酸化級(jí)聯(lián)反應(yīng)的功能性交匯點(diǎn),研究表明醛固酮可刺激SGK-1介導(dǎo)腎臟炎癥反應(yīng)及纖維化[9]。在梗阻性腎病大鼠實(shí)驗(yàn)中,醛固酮活化誘導(dǎo)SGK-1在腎組織中表達(dá)增強(qiáng)[10-11],導(dǎo)致氧化應(yīng)激、炎性損傷,并上調(diào)促纖維化因子CTGF的表達(dá),引起MMPs/TIMPs的失衡,加速臟器纖維化進(jìn)程[12]。故SGK-1目前被認(rèn)為是醛固酮促臟器纖維化、氧化應(yīng)激及炎性損傷的主要效應(yīng)介質(zhì)[13]。亦有研究表明梗阻性腎病動(dòng)物中腎小管上皮細(xì)胞的表型轉(zhuǎn)化與SGK-1的上調(diào)密切相關(guān),敲除SGK-1基因可減輕UUO誘導(dǎo)的細(xì)胞表型轉(zhuǎn)化[11]。SGK-1主要參與細(xì)胞內(nèi)信號(hào)傳導(dǎo),與NF-кB的活化密切相關(guān),有研究提示醛固酮可通過SGK-1誘導(dǎo)大鼠系膜細(xì)胞促纖維化因子CTGF分泌及NF-κB的活化[14]。醛固酮活化誘導(dǎo)的炎性損傷可通過SGK-1/NF-κB信號(hào)通路促纖維化,故SGK-1在醛固酮促纖維化中發(fā)揮著重要作用[15]。本研究主要觀察醛固酮誘導(dǎo)的細(xì)胞增殖以及信號(hào)傳導(dǎo),結(jié)果顯示梗阻性腎病誘導(dǎo)的醛固酮活化通過SGK-1通路刺激腎小管上皮細(xì)胞增殖,參與纖維化的進(jìn)展,給予依普利酮治療后,細(xì)胞增殖得以抑制,其作用與下調(diào)SGK-1相關(guān)。
此外,經(jīng)典途徑TGF-β1作為重要的致纖維化細(xì)胞生長因子,對(duì)細(xì)胞增殖的作用依然存在,其高表達(dá)是Ang II還是醛固酮誘導(dǎo)尚需進(jìn)一步證實(shí),但通過抑制醛固酮活性,可以同時(shí)下調(diào)其表達(dá),抑制細(xì)胞的增殖,減輕纖維化病變。
新型鹽皮質(zhì)激素受體阻斷劑依普利酮與螺內(nèi)酯相比,具有高度選擇性,可競(jìng)爭(zhēng)性抑制鹽皮質(zhì)激素受體與醛固酮的結(jié)合,從而阻止醛固酮受體復(fù)合物的形成及活化所誘導(dǎo)的腎間質(zhì)纖維化進(jìn)程。對(duì)腎臟具有一定的保護(hù)作用[9、16]。已有實(shí)驗(yàn)證實(shí),依普利酮可有效抑制醛固酮的活化,抑制細(xì)胞增殖和細(xì)胞外基質(zhì)過度分泌,保護(hù)腎功能[17-18]。本實(shí)驗(yàn)主要通過采用UUO方式復(fù)制腎間質(zhì)纖維化模型,激活RAAS系統(tǒng),誘導(dǎo)醛固酮活化上調(diào)SGK-1表達(dá)介導(dǎo)腎小管上皮細(xì)胞增殖作用,研究其阻斷劑依普利酮可通過下調(diào)SGK-1表達(dá)抑制梗阻性腎病細(xì)胞增殖從而達(dá)到減輕腎間質(zhì)纖維化的作用。之前我們?cè)^察依普利酮通過下調(diào)TNF-α、NF-κB抑制細(xì)胞表型轉(zhuǎn)化,減輕腎間質(zhì)纖維化的作用[16],這次研究以細(xì)胞增殖為重點(diǎn),觀察醛固酮活化上調(diào)SGK-1表達(dá)對(duì)細(xì)胞增殖標(biāo)記物增殖細(xì)胞核抗原( PCNA)的作用。結(jié)果顯示依普利酮可通過下調(diào)SGK-1、TGF-β1的表達(dá),抑制細(xì)胞的增殖及ECM的沉積,從而減緩腎間質(zhì)纖維化的進(jìn)程,減輕腎臟損傷。
(致謝:衷心感謝河北省中西醫(yī)結(jié)合肝腎病重點(diǎn)實(shí)驗(yàn)室各位老師的支持與幫助。)
參考文獻(xiàn):
[1]Eddy A A.Molecular basis of renal fibrosis[J].Pediatr Nephrol,2000,15( 3-4) : 290-301.
[2]Rafiq K,Hitomi H,Nakano D,Nishivama A.Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney [J].J Pharmacol Sci,2011,115( 1) : 1-7.
[3]Yang J,Liu Y.Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis[J].Am J Pathol,2001,159( 4) : 1465-75.
[4]Kolesnyk I,Struijk D G,Dekker F W,et al.Effects of angiotensinconverting enzyme inhibitors and angiotensinⅡreceptor blockers in patients with chronic kidney disease[J].Neth J Med,2010,68( 1) : 15-23.
[5]Bolignano D,Palmer S C,Navaneethan S D,et al.Aldosterone antagonists for preventing the progression of chronic kidney disease [J].Cochrane Database Syst Rev,2014,Apr 29; 4: CD007004.
[6]崔艷,陳曉,安惠霞,等.醛固酮與腎臟炎癥的研究進(jìn)展[J].中國中西醫(yī)結(jié)合腎病雜志,2012,13( 10) : 932-4.
[6]Cui Y,Chen X,An H X,et al.The research progress of aldosterone and kidney inflammation[J].Chin J Integ Trad Western Nephrol,2012,13( 10) : 932-4.
[7]韓琳,秦建國,陳志強(qiáng),等.鱉甲煎丸對(duì)腎間質(zhì)纖維化大鼠細(xì)胞增殖的影響[J].北京中醫(yī)藥大學(xué)學(xué)報(bào),2009,32( 7) : 457-61.
[7]Han L,Qin J G,Chen Z Q,et al.Influence of Bie jia jian pills on cell proliferation in rats with renal interstitial fibrosis[J].J Beijing Univ Tradit Chin Med,2009,32( 7) : 457-61.
[8]董健平,陳香美,師鎖柱,等.金屬蛋白酶組織抑制劑1在大鼠腎小管間質(zhì)損害中的表達(dá)及其意義[J].中華腎臟病雜志,2002,18( 4) : 275-9.
[8]Dong J P,Chen X M,Shi S Z,et al.Role of TIMP-1 expression in renal tubulointerstital lesion induced by unilateral ureteral obstruction[J].Chin J Nephrol,2002,18( 4) : 275-9.
[9]Terada Y,Kuwana H,Kobayashi T,et al.Aldosterone stimulated SGK 1 activity mediates profibrotic signaling in the mesangium[J].J Am Soc Nephrol,2008,19( 2) : 298-309.
[10]王箏,梁麗娟,王聰慧,等.腎絡(luò)通對(duì)梗阻性腎病大鼠炎性介質(zhì)及血清糖皮質(zhì)激素誘導(dǎo)蛋白激酶1表達(dá)的影響[J].中醫(yī)雜志,2014,55( 1) : 53-6.
[10]Wang Z,Liang L J,Wang C H,et al.Effects of shenluotong on inflammatory mediators and serum glucocorticoid-induced protein kinase 1 in rats with obstructive nephropathy[J].J TCM,2014,55 ( 1) : 53-6.
[11]Cheng J Z,Truong L D,Wu X Q,et al.Serum and glucocorticoidregulated kinase 1 is upregulated following unilateral ureteral obstruction causing epithelial-mesenchymal transition[J].Kidney Int,2010,78( 7) : 668-78.
[12]Martín-Fernández B,de las Heras N,Miana M,et al.Structural,functional,and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression[J].J Cardiovasc Pharmacol,2011,57( 1) : 114-21.
[13]Martín-Fernández B,de las Heras N,Miana M,et al.Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum-and glucocorticoid-regulated kinase type 1[J].Exp Physiol,2012,97( 6) : 710 -8.
[14]Terada Y,Ueda S,Hamada K,et al.Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum-and glucocorticoid-inducible protein kinase-1[J].Clin Exp Nephrol,2012,16( 1) : 81-8.
[15]Samavat S,Ahmadpoor P,Samadian F.Aldosterone,hypertension,and beyond[J].Iran J Kidney Dis,2011,5( 2) : 71-6.
[16]梁麗娟,王箏,王蕊,等.依普利酮下調(diào)TNF-α、NF-κB抑制細(xì)胞表型轉(zhuǎn)化的研究[J].中國藥理學(xué)通報(bào),2013,29( 11) : 1553 -7.
[16]Liang L J,Wang Z,Wang R,et al.Inhibitory effects of eplerenone on epithelial-mesenchymal transformation via down-regulated TNF-α and NF-κB in rats with unilateral ureteral obstruction[J].Chin Pharmacol Bull,2013,29( 11) : 1553-7.
[17]孫東云,許慶友,王香婷,等.依普利酮抑制細(xì)胞增殖拮抗急性環(huán)孢素A腎損傷的研究[J].中國藥理學(xué)通報(bào),2011,27( 12) : 1678-82.
[17]Sun D Y,Xu Q Y,Wang X T,et al.Inhibitory effect of eplerenone on cell proliferation in acute cyclosporine nephrotoxicity [J].Chin Pharmacol Bull,2011,27( 12) : 1678-82.
[18]Chen H,Sun F,Zhong X,et al.Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation,interstitial cell proliferation and oxidative stress[J].Kidney Blood Press Res,2013,37( 6) : 557-66.
Inhibitory effects of eplerenone on cell proliferation via down-regulated SGK-1 pathway in rats with unilateral ureteral obstruction
WU Li-min1,2,CHEN Li-xiang1,LIANG Li-juan1,WANG Zheng2,WANG Miao1,LIU Shao-wei2,XIONG Yun-zhao1,WANG Xuan1,XU Qing-you1,2
( 1.Hebei Medical University Graduate School,Shijiazhuang 050091,China; 2.College of Integrated Chinese and Western Medicine,Hebei University of Chinese Medicine,Hebei Key Laboratory of Integrative Medicine on Liver-kidney patterns,Shijiazhuang 050091,China)
Abstract:AimTo observe the effect of mineralocorticoid receptor blockade eplerenone on cell proliferation in obstructed kidney of rats.Methods Renal interstitial fibrotic animals were made with unilateral ureteral obstruction ( UUO) and treated with eplerenone100 mg ·kg-1·d-1.The kidneys were harvested on the 10th day and proliferating cell nuclear antigen ( PCNA),serum and glucocorticoid induced kinase-1 ( SGK-1) and transforming growth factor-β1 ( TGF-β1) were detected with immunohistochemistry and Western blot.ResultsRenal histopathology showed large quantities extracellular matrix ( ECM) accumulation in kidney with UUO,large numbers of inflammatory cells infiltrated in renal interstitium,renal tubular expansion and exfoliation of epithelial cells.The cell proliferation and ECM accumulation were inhibited in eplerenone treated rats significantly.Immunohistochemistry and Western blot showed that expressions of PCNA,SGK-1 and TGF-β1were significantly up-regulated with UUO and down-regulated by eplerenone.ConclusionEplerenone plays the role in inhibiting the cell proliferation and reducing ECM accumulation by down-regulating expression of SGK-1 pathway in rats with unilateral ureteral obstruction.
Key words:eplerenone; renal interstitial fibrosis; cell proliferation; UUO; PCNA; SGK-1; TGF-β1
作者簡(jiǎn)介:吳麗敏( 1989-),女,碩士生,研究方向:腎臟病中西醫(yī)結(jié)合臨床及基礎(chǔ),Tel: 0311-89926298,E-mail: 916952722 @ qq.com;
基金項(xiàng)目:國家自然科學(xué)基金資助項(xiàng)目( No 81273684,81473652),河北省自然科學(xué)基金資助項(xiàng)目( No H2015423009)
收稿日期:2015-09-06,修回日期: 2015-11-26
文獻(xiàn)標(biāo)志碼:A
文章編號(hào):1001-1978( 2016) 01-0069-05中國圖書分類號(hào): R-332; R322.61; R341; R692.39; R977. 6摘要:目的觀察鹽皮質(zhì)激素受體阻斷劑依普利酮抑制梗阻性實(shí)驗(yàn)動(dòng)物腎臟細(xì)胞增殖的作用及機(jī)制。方法結(jié)扎大鼠單側(cè)輸尿管( UUO)制備腎間質(zhì)纖維化動(dòng)物模型,給予依普利酮100 mg·kg-1·d-1治療,10 d后摘取腎臟,觀察大鼠腎臟組織病理改變。采用免疫組化、Western blot方法檢測(cè)增殖細(xì)胞核抗原( PCNA)、血清糖皮質(zhì)激素誘導(dǎo)蛋白激酶1 ( SGK-1)、轉(zhuǎn)化生長因子-β1( TGF-β1)的表達(dá)。結(jié)果腎臟病理顯示,UUO組大鼠腎臟有明顯的細(xì)胞外基質(zhì)( ECM)積聚,有大量炎性細(xì)胞浸潤,腎小管擴(kuò)張明顯,上皮細(xì)胞脫落,依普利酮可明顯減輕其細(xì)胞增殖及ECM的沉積;免疫組化和Western blot結(jié)果顯示,UUO組大鼠腎臟PCNA、SGK-1、TGF-β1表達(dá)明顯增強(qiáng);依普利酮可下調(diào)其表達(dá)。結(jié)論依普利酮可通過下調(diào)SGK-1的表達(dá),抑制梗阻性腎病細(xì)胞增殖,減少ECM的沉積,減緩腎臟纖維化的進(jìn)程,減輕腎臟損傷。
doi:10.3969/j.issn.1001-1978.2016.01.015